RLMD Relmada Therapeutics Inc

Price (delayed)

$3.78

Market cap

$403.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$391.88M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 43
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to making a difference in ...

Highlights
The quick ratio has soared by 62% from the previous quarter
The EPS has soared by 59% YoY and by 17% from the previous quarter
Relmada Therapeutics's net income has increased by 9% YoY but it has decreased by 5% QoQ
RLMD's equity is down by 6% from the previous quarter

Key stats

What are the main financial stats of RLMD

RLMD stock price

How has the Relmada Therapeutics stock price performed over time
Intraday
-10.85%
1 week
-10.43%
1 month
-18.36%
1 year
126.35%
YTD
-21.74%
QTD
-45.38%

Financial performance

How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.13M
Net income
-$61.93M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's net income has increased by 9% YoY but it has decreased by 5% QoQ
Relmada Therapeutics's operating income has decreased by 8% from the previous quarter but it has increased by 8% YoY

Price vs fundamentals

How does RLMD's price correlate with its fundamentals

Growth

What is Relmada Therapeutics's growth rate over time

Valuation

What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 59% YoY and by 17% from the previous quarter
The P/B is 52% less than the last 4 quarters average of 4.5 and 17% less than the 5-year quarterly average of 2.6
RLMD's equity is down by 6% from the previous quarter

Efficiency

How efficient is Relmada Therapeutics business performance
RLMD's return on invested capital has surged by 79% year-on-year and by 34% since the previous quarter
Relmada Therapeutics's return on equity has surged by 79% YoY and by 33% QoQ
The ROA has soared by 76% year-on-year and by 32% since the previous quarter

Dividends

What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLMD.

Financial health

How did Relmada Therapeutics financials performed over time
RLMD's total liabilities has soared by 142% YoY but it is down by 25% QoQ
The quick ratio has soared by 62% from the previous quarter
RLMD's debt is 100% smaller than its equity
RLMD's equity is down by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.